MXPA02003162A - Solucion de calcitrol estable para empaque en frascos. - Google Patents

Solucion de calcitrol estable para empaque en frascos.

Info

Publication number
MXPA02003162A
MXPA02003162A MXPA02003162A MXPA02003162A MXPA02003162A MX PA02003162 A MXPA02003162 A MX PA02003162A MX PA02003162 A MXPA02003162 A MX PA02003162A MX PA02003162 A MXPA02003162 A MX PA02003162A MX PA02003162 A MXPA02003162 A MX PA02003162A
Authority
MX
Mexico
Prior art keywords
packaging
vials
stable
solution
calcitriol solution
Prior art date
Application number
MXPA02003162A
Other languages
English (en)
Inventor
Edward C Shinal
Original Assignee
Aaipharma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Aaipharma Inc filed Critical Aaipharma Inc
Publication of MXPA02003162A publication Critical patent/MXPA02003162A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/59—Compounds containing 9, 10- seco- cyclopenta[a]hydrophenanthrene ring systems
    • A61K31/593—9,10-Secocholestane derivatives, e.g. cholecalciferol, i.e. vitamin D3
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/02—Nutrients, e.g. vitamins, minerals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
    • A61P3/14—Drugs for disorders of the metabolism for electrolyte homeostasis for calcium homeostasis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Diabetes (AREA)
  • Dermatology (AREA)
  • Nutrition Science (AREA)
  • Endocrinology (AREA)
  • Medical Preparation Storing Or Oral Administration Devices (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Food Preservation Except Freezing, Refrigeration, And Drying (AREA)
MXPA02003162A 1999-09-29 2000-09-26 Solucion de calcitrol estable para empaque en frascos. MXPA02003162A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US09/408,970 US6211169B1 (en) 1999-09-29 1999-09-29 Stable calcitriol solution for packaging into vials
PCT/US2000/026417 WO2001022998A1 (en) 1999-09-29 2000-09-26 Stable calcitriol solution for packaging in vials

Publications (1)

Publication Number Publication Date
MXPA02003162A true MXPA02003162A (es) 2003-08-20

Family

ID=23618517

Family Applications (1)

Application Number Title Priority Date Filing Date
MXPA02003162A MXPA02003162A (es) 1999-09-29 2000-09-26 Solucion de calcitrol estable para empaque en frascos.

Country Status (12)

Country Link
US (1) US6211169B1 (es)
EP (1) EP1216057B1 (es)
JP (1) JP2003510293A (es)
AT (1) ATE253940T1 (es)
AU (1) AU7616200A (es)
CA (1) CA2388438A1 (es)
DE (1) DE60006558T2 (es)
ES (1) ES2204692T3 (es)
MX (1) MXPA02003162A (es)
NO (1) NO20021402D0 (es)
PT (1) PT1216057E (es)
WO (1) WO2001022998A1 (es)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002022136A1 (en) * 2000-09-18 2002-03-21 F H Faulding & Co Limited Diphosphonate solutions
BR0214679A (pt) * 2001-12-03 2004-12-14 Novacea Inc Composições farmacêuticas compreendendo compostos a base de vitamina d ativa
US7148211B2 (en) * 2002-09-18 2006-12-12 Genzyme Corporation Formulation for lipophilic agents
US20040053895A1 (en) * 2002-09-18 2004-03-18 Bone Care International, Inc. Multi-use vessels for vitamin D formulations
US20040058895A1 (en) * 2002-09-18 2004-03-25 Bone Care International, Inc. Multi-use vessels for vitamin D formulations
US20050026877A1 (en) * 2002-12-03 2005-02-03 Novacea, Inc. Pharmaceutical compositions comprising active vitamin D compounds
US20060217316A1 (en) * 2003-04-02 2006-09-28 Ragab El-Rashidy Method for the treatment of prostate cancer
US20050020546A1 (en) * 2003-06-11 2005-01-27 Novacea, Inc. Pharmaceutical compositions comprising active vitamin D compounds
KR20130103489A (ko) * 2010-08-06 2013-09-23 호스피라 오스트레일리아 피티와이 리미티드 바이알 제조 방법 및 시스템
SI2680832T1 (sl) 2011-03-04 2019-11-29 Gruenenthal Gmbh Vodna farmacevtska formulacija tapentadola za peroralno dovajanje
WO2013114003A1 (fr) * 2012-01-30 2013-08-08 Laboratoires Urgo Procede de preparation d'un produit sirupeux comprenant des vitamines
WO2015119183A1 (ja) * 2014-02-05 2015-08-13 協和発酵キリン株式会社 活性型ビタミンｄ３またはその誘導体を含有する液剤
CN107847471A (zh) 2015-03-27 2018-03-27 格吕伦塔尔有限公司 他喷他多肠胃外给药的稳定制剂
EP3515412A1 (en) 2016-09-23 2019-07-31 Grünenthal GmbH Stable formulation for parenteral administration of tapentadol
CN116077432B (zh) * 2023-02-21 2023-09-08 正大制药（青岛）有限公司 一种骨化三醇口服溶液及其制备方法

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4308264A (en) * 1981-01-28 1981-12-29 Abbott Laboratories Stabilized, dilute aqueous preparation of 1α,25-dihydroxycholecalciferol for neonatal administration
US4420092A (en) 1982-09-01 1983-12-13 Mpl Inc. Tamper-resistant pharmaceutical vial and cap assembly
JP2545540B2 (ja) * 1987-05-29 1996-10-23 株式会社 大協精工 両面ラミネ−トゴム栓
US5230429A (en) 1990-12-13 1993-07-27 Etheredge Iii Robert W Tamper-evident injectable drug vial
JPH05238936A (ja) * 1992-02-27 1993-09-17 Dainippon Pharmaceut Co Ltd カルシトリオールの水性液剤
AU5861396A (en) 1995-05-19 1996-11-29 Abbott Laboratories Stable aqueous formulations of 1alpha,25-dihydroxycholecalci ferol for parenteral administration
US6051567A (en) * 1999-08-02 2000-04-18 Abbott Laboratories Low oxygen content compositions of 1α, 25-dihydroxycholecalciferol

Also Published As

Publication number Publication date
US6211169B1 (en) 2001-04-03
EP1216057A1 (en) 2002-06-26
AU7616200A (en) 2001-04-30
NO20021402L (no) 2002-03-20
JP2003510293A (ja) 2003-03-18
PT1216057E (pt) 2004-04-30
EP1216057B1 (en) 2003-11-12
ES2204692T3 (es) 2004-05-01
DE60006558D1 (de) 2003-12-18
DE60006558T2 (de) 2004-05-13
CA2388438A1 (en) 2001-04-05
NO20021402D0 (no) 2002-03-20
ATE253940T1 (de) 2003-11-15
WO2001022998A1 (en) 2001-04-05

Similar Documents

Publication Publication Date Title
MXPA02003162A (es) Solucion de calcitrol estable para empaque en frascos.
SE9904505D0 (sv) Novel compounds
NZ516347A (en) Indanyl-substituted benzenecarboxamides, process for their preparation, their use as a medicament and pharmaceutical formulations containing them
MXPA03007712A (es) Sales farmaceuticas.
BR0205721A (pt) Formulações de oximorfona de liberação controlada
DE60018100D1 (en) Polymorphe form von atorvastatin-calcium
YU69603A (sh) Atorvastatin kalcijum u farmaceutskom obliku, njegovoj smeši i farmaceutskoj formulaciji, koja sadrži atorvastatin kalcijum
IL162213A0 (en) Pharmaceutical compositions containing active vitamin d compounds
YU68199A (sh) Farmaceutske formulacije koje sadrže vorikonazol
GEP20053473B (en) High Potency Dihydroergotamine Compositions
SE9704546D0 (sv) Novel compounds
ZA200405657B (en) Formulation & dosage form for the controlled delivery of therapeutic agents.
SE9702001D0 (sv) Novel compounds
AU2580001A (en) Blister package for pharmaceutical treatment card
AP1787A (en) Novel perindopril salt and pharmaceutical compositions containing same.
IL101358A0 (en) Crystalline tiagabine hydrochloride monohydrate,its preparation and pharmaceutical compositions containing it
GB0109122D0 (en) Novel compounds
AU2924699A (en) Tryptase inhibitors
MXPA04005552A (es) Analogos de vitamina d.
GB9907571D0 (en) Compounds
EP0869786A4 (en) PHARMACEUTICAL COMPOUNDS
YU48200A (sh) Farmaceutski preparati
IL134039A0 (en) Polyhydroxybutylpyrazines, their preparation and medicines containing them
EP0948961A3 (de) Calciumhaltige Brausetablette mit einem Antihistaminikum als Wirkstoff
HK135494A (en) Azelastin embonate, process for its preparation and pharmaceutical compositions containing azelastin embonate as the active ingredient

Legal Events

Date Code Title Description
FG Grant or registration